Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Crystal Gateway Marriott

23 sep 2026 8:15 a.m. - 25 sep 2026 12:45 p.m.

1700 Richmond Highway, Arlington, VA 22202, USA

Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

Session 6 Track 2: Mind Over Matter: Cracking the Code of CNS Delivery

Session Chair(s)

Aimee L. Jackson, PHD

Aimee L. Jackson, PHD

, Miragen Therapeutics, United States

Considerations for the distribution and safety of oligonucleotide therapeutics for CNS applications.

Learning Objective :
  • Compare the distribution and safety profiles of oligos delivered systemically or directly into the CSF
  • Identify the opportunities and challenges of different approaches to delivering oligonucleotides to the brain; when does systemic administration for BBB transit make sense and when is local administration the better choice?
  • Apply stability, PK/PD, and safety information to identify the optimal approaches to targeting brain diseases

Speaker(s)

Representative Invited

Representative Invited

Director, Toxicology, Denali Therapeutics, United States

Speaker

Representative Invited

Representative Invited

Toxicologist, Ionis Pharmaceuticals, Inc., United States

Speaker

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.